Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Continuation or reintroduction of an antineoplastic strategy after documented disease progression.

Markman M.

Oncology. 2013;85(6):348-9. doi: 10.1159/000357057. Epub 2013 Dec 6. No abstract available.

2.

Dodging a dogma: is treating beyond progression beneficial?

Naing A, Kurzrock R.

Cancer Chemother Pharmacol. 2013 May;71(5):1385-6. doi: 10.1007/s00280-013-2123-z. Epub 2013 Feb 27. No abstract available.

PMID:
23443308
3.

A need to document a role for palliative chemotherapy in the management of progressive malignant disease.

Markman M.

Oncology. 2007;72(3-4):162-3. Epub 2007 Dec 20. No abstract available.

PMID:
18097166
4.

Progressive thoughts about progressive disease.

Shah NP.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5229-31. No abstract available.

5.

Continuation of trastuzumab beyond disease progression.

Montemurro F, Faggiuolo R, Redana S, Donadio M, Minischetti M, Durando A, Vietti-Ramus G, Buosi R, Aglietta M.

J Clin Oncol. 2005 Apr 20;23(12):2866-8; discussion 2868-9. No abstract available.

PMID:
15838006
6.

Re: Biology of cachexia.

Wheeler BM.

J Natl Cancer Inst. 1998 Apr 15;90(8):628. No abstract available.

PMID:
9554447
7.

Effects of cancer drugs on survival: often poorly evaluated.

[No authors listed]

Prescrire Int. 2009 Aug;18(102):180-3.

PMID:
19746577
8.

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

Rubinstein LV, Dancey JE, Korn EL, Smith MA, Wright JJ.

J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. Epub 2007 Sep 25. No abstract available.

PMID:
17895470
9.

Apoptosis: its role in the progression of and chemotherapy for carcinoma.

Meterissian SH.

J Am Coll Surg. 1997 Jun;184(6):658-66. Review. No abstract available.

PMID:
9179126
10.

Clinical development of temsirolimus, a novel mTOR inhibitor, for treatment of advanced malignancies.

Dancey JE.

Semin Oncol. 2009 Dec;36 Suppl 3:S1-2. doi: 10.1053/j.seminoncol.2009.10.014. No abstract available.

PMID:
19963095
11.

[New systemic therapies in oncology].

Zaman K, Ketterer N, Vulliémoz D, Stupp R, Leyvraz S.

Rev Med Suisse. 2005 May 18;1(20):1361-2, 1364-5. Review. French.

PMID:
15991629
12.

Is it rational to continue anti-neoplastics with minimal toxicity even after progression in patients with no other options? Possibly yes.

Sezer A, Sumbul AT, Abali H.

Asian Pac J Cancer Prev. 2014;15(2):1061-2. No abstract available.

13.

Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.

Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J.

Cancer J. 2009 Sep-Oct;15(5):386-94. doi: 10.1097/PPO.0b013e3181b9c5ec. Review.

PMID:
19826358
14.

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.

Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P.

BJU Int. 2010 Oct;106(7):974-8. doi: 10.1111/j.1464-410X.2010.09296.x. Epub 2010 Mar 9.

15.

BMS and Exelixis target tumor suppression pathways.

[No authors listed]

Expert Rev Anticancer Ther. 2001 Aug;1(2):167. No abstract available.

PMID:
12113021
16.

Mathematical modeling of cancer progression and response to chemotherapy.

Sanga S, Sinek JP, Frieboes HB, Ferrari M, Fruehauf JP, Cristini V.

Expert Rev Anticancer Ther. 2006 Oct;6(10):1361-76. Review.

PMID:
17069522
17.

Criticism of tumor response criteria raises trial design questions.

Twombly R.

J Natl Cancer Inst. 2006 Feb 15;98(4):232-4. No abstract available.

PMID:
16478740
18.

[Strategy of antineoplastic chemotherapy].

Anger G, Wutke K.

Z Gesamte Inn Med. 1977 Oct 1;32(19):483-6. German.

PMID:
595719
19.

Progression-free survival remains debatable endpoint in cancer trials.

Tuma R.

J Natl Cancer Inst. 2009 Nov 4;101(21):1439-41. doi: 10.1093/jnci/djp399. Epub 2009 Oct 14. No abstract available.

PMID:
19828873
20.

Infusion nurses society position paper. Administration of antineoplastic agents.

[No authors listed]

J Infus Nurs. 2002 Mar-Apr;25(2):83-5.

PMID:
11984221

Supplemental Content

Support Center